SYRE - CIK 0001636282
Spyre Therapeutics, Inc. (SYRE) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $0.00 | - |
| FY 2024 | $0.00 | -100.0% |
| FY 2023 | $886.00K | -62.0% |
| FY 2022 | $2.33M | -87.6% |
| FY 2021 | $18.74M | - |
| FY 2020 | $0.00 | - |
| FY 2019 | $0.00 | -100.0% |
| FY 2018 | $3.89M | -25.3% |
| FY 2017 | $5.21M |
Spyre Therapeutics, Inc. (SYRE) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Spyre Therapeutics, Inc.'s revenue declined from $4.63M to $0.00.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| +12.5% |
| FY 2016 | $4.63M | - |